Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Retrospective Chart Review of First-time Opsumit (Macitentan) Users in the United States

Next Previous
X
Search
Trial Profile

Multicenter, Retrospective Chart Review of First-time Opsumit (Macitentan) Users in the United States

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms OrPHeUS
  • Sponsors Actelion Pharmaceuticals

    • Most Recent Events

    • 29 Aug 2022 Results assessing the demographics, clinical characteristics, safety, tolerability, and outcomes associated with initiation of the ERA macitentan and the PDE5i tadalafil in patients with comorbidities in the US OPsumit USers (OPUS) and the OPsumit Historical USers cohort (OrPHeUS) combined dataset, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
    • 19 May 2021 Real-world data from OPUS & Orpheus studies were used to describe pulmonary arterial hypertension patient characteristics and treatment patterns across four US regions, presented at the 117th International Conference of the American Thoracic Society.
    • 17 May 2021 Study insights from OPUS (NCT02126943) / ORPHEUS (NCT03197688), presented at the 70th Annual Scientific Session of the American College of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top